Evvy Secures $40 Million Series B to Push Women’s Health Forward with Vaginal Microbiome Data

On Tuesday, women’s‑health startup Evvy announced it had raised a $40 million Series B round, with Catalio Capital Management taking the lead. The fresh capital is earmarked for scaling the company’s at‑home, CLIA‑ and CLEP‑certified metagenomic sequencing test that looks at the vaginal microbiome with a single swab.

Founded in 2021 by Priyanka Jain, Laine Bruzek and Pita Navarro, Evvy has been quietly building what it calls the only home‑based mNGS test for vaginal microbes. Users collect a swab, mail it to Evvy’s lab, and receive a report that not only lists the bacterial species but also offers a clinical interpretation, suggested next steps and, when appropriate, a personalized prescription.

“When a patient opens their portal they see the raw data, a diagnosis and a clear path forward,” Jain told TechCrunch. “If medication is needed, we can even route that through a telehealth provider on our platform.”

Since its launch the company says it’s served over 100 000 patients across the United States and partnered with roughly 3 000 clinicians. The data‑driven approach has already produced 15 peer‑reviewed papers, uncovered novel bacterial sub‑types of bacterial vaginosis, and added hundreds of previously unknown vaginal‑microbiome genomes to public databases.

But Evvy’s ambition goes beyond a single test result. Jain explained that the real value lies in stitching together microbiome signatures, symptoms, treatments and outcomes into a living, learning dataset. “Right now precision medicine for women is built on data that simply didn’t measure female biology,” she said. “We need AI to mine that massive, longitudinal data and surface patterns that traditional research missed.”

In May, the company rolled out EvvyAI, an artificial‑intelligence‑powered assistant that translates the lab’s findings into plain‑language advice and nudges users toward a clinician when a question is beyond its scope. The AI is meant to act as a first‑line guide, not a replacement for professional care.

With the new funding, Evvy is also stepping into the fertility arena. The startup is already running a prospective study that pairs its vaginal‑microbiome test with IVF clinics, looking for links to implantation success, pre‑term birth risk and recurrent pregnancy loss. Jain hopes the data will eventually help women say goodbye to “unexplained infertility” and other cryptic diagnoses that currently leave patients frustrated.

Evvy isn’t the only player trying to democratize vaginal health – firms like Juno Bio, Tiny Health and Daye are also building at‑home kits. Still, Jain envisions something broader: a next‑generation Pap smear that can be done at home, giving regular, data‑rich snapshots of infection, inflammation, hormone balance, HPV status and more.

“We can’t wait for the old research pipeline to catch up,” she said. “Women should be part of the solution, not just the problem.”